The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCAR-T 2023 | Updates in multiple myeloma
In this session, experts Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, Nizar Bahlis, MD, University of Calgary, Calgary, Canada, and Sham Mailankody, MBBS, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comment on some of the most exciting advances in the field of CAR-T therapy for multiple myeloma, covering updates in both BCMA and non-BCMA CAR-T therapy and bispecific antibodies. They then move to mechanisms of resistance to BCMA bispecific antibodies and managing treatment-related toxicities. This discussion took place at the 5th International Workshop on CAR-T (iwCAR-T) 2023 held in Scottsdale, AZ.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
